NASDAQ:ASMB - Assembly Biosciences Stock Price, Forecast & News

Assembly Biosciences trades on the NASDAQ under the ticker symbol "ASMB."

Assembly Biosciences Inc (NASDAQ:ASMB) released its earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.93) by $0.03. The biopharmaceutical company had revenue of $4.23 million for the quarter, compared to analyst estimates of $3.45 million. Assembly Biosciences had a negative return on equity of 52.83% and a negative net margin of 647.72%. View Assembly Biosciences' Earnings History.

Assembly Biosciences is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Assembly Biosciences.

4 equities research analysts have issued 1 year target prices for Assembly Biosciences' stock. Their forecasts range from $20.00 to $74.00. On average, they expect Assembly Biosciences' share price to reach $41.33 in the next twelve months. This suggests a possible upside of 135.0% from the stock's current price. View Analyst Price Targets for Assembly Biosciences.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Assembly Biosciences in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Assembly Biosciences.

News coverage about ASMB stock has been trending very negative on Tuesday, InfoTrie reports. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Assembly Biosciences earned a news impact score of -3.9 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Assembly Biosciences.

Assembly Biosciences saw a increase in short interest during the month of November. As of November 15th, there was short interest totalling 2,290,000 shares, an increase of 477.3% from the October 31st total of 396,700 shares. Based on an average daily trading volume, of 548,000 shares, the days-to-cover ratio is currently 4.2 days. Approximately 10.1% of the company's shares are sold short. View Assembly Biosciences' Current Options Chain.

Some companies that are related to Assembly Biosciences include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Allergan (AGN), Zoetis (ZTS), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), The Medicines (MDCO), Horizon Therapeutics (HZNP), Nektar Therapeutics (NKTR) and Zogenix (ZGNX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Assembly Biosciences investors own include Progenics Pharmaceuticals (PGNX), AVEO Pharmaceuticals (AVEO), Exelixis (EXEL), Tandem Diabetes Care (TNDM), FibroGen (FGEN), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS), Lexicon Pharmaceuticals (LXRX) and Nektar Therapeutics (NKTR).

Assembly Biosciences' stock is owned by a variety of of retail and institutional investors. Top institutional investors include State Street Corp (1.74%), Emerald Advisers LLC (1.70%), Emerald Mutual Fund Advisers Trust (1.61%), Barclays PLC (0.29%), Squarepoint Ops LLC (0.23%) and Russell Investments Group Ltd. (0.23%). Company insiders that own Assembly Biosciences stock include Derek A Small, Uri A Lopatin and William R Ringo. View Institutional Ownership Trends for Assembly Biosciences.

ASMB stock was sold by a variety of institutional investors in the last quarter, including Valeo Financial Advisors LLC, Assenagon Asset Management S.A., Barclays PLC, Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust and Alps Advisors Inc.. View Insider Buying and Selling for Assembly Biosciences.

ASMB stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Squarepoint Ops LLC, Voloridge Investment Management LLC, State Street Corp, Rhumbline Advisers and Millennium Management LLC. View Insider Buying and Selling for Assembly Biosciences.

Shares of ASMB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ASMB stock can currently be purchased for approximately $17.59.

Assembly Biosciences has a market capitalization of $458.22 million and generates $14.80 million in revenue each year. The biopharmaceutical company earns $-90,750,000.00 in net income (profit) each year or ($3.98) on an earnings per share basis. Assembly Biosciences employs 95 workers across the globe.View Additional Information About Assembly Biosciences.

The official website for Assembly Biosciences is http://www.assemblybio.com/.

Assembly Biosciences' mailing address is 11711 NORTH MERIDIAN STREET SUITE 310, CARMEL IN, 46032. The biopharmaceutical company can be reached via phone at 833-509-4583 or via email at [email protected]